Stem Cell Therapy for Angina Pectoris
Stem cells provide new hope for recovery and symptom relief in angina pectoris.
Stem Cell Treatment for Angina Pectoris
Angina pectoris is a heart condition marked by chest pain or discomfort, usually caused by reduced blood flow to the heart. It can result from several factors, including narrowing of the coronary arteries, stress, or other underlying health conditions. Angina affects individuals of different ages and can significantly impact overall well-being and quality of life.
​
Our stem cell treatment for angina pectoris involves the precise administration of allogeneic mesenchymal stem cells (MSCs), including those derived from umbilical cord tissue, to address the underlying causes and improve cardiovascular health. MSCs possess the unique ability to differentiate into various cell types and release growth factors that support tissue repair and regeneration. This regenerative capacity makes them particularly effective in enhancing blood flow and improving heart function.
​
By combining advanced techniques with MSC and umbilical cord stem cell therapy, we offer a comprehensive approach to managing angina pectoris. This innovative treatment aims to reduce symptoms, improve heart performance, and enhance overall quality of life. At our clinic, our focus is on promoting long-term heart health and delivering patient-centered care through cutting-edge stem cell therapies.
How is our stem cell therapy transplant for angina pectoris performed in Istanbul?
​
Ongoing research is exploring the potential of stem cell therapy as a treatment for refractory angina, a condition that can be especially difficult to manage. Studies have demonstrated that hematopoietic stem cells may provide relief for patients with this challenging condition. In a Phase II clinical trial, patients who received injections of umbilical cord-derived mesenchymal stem cells (MSCs) showed significantly better outcomes compared to those who received placebo treatments. These findings highlight the strong potential of MSC therapy as an effective solution for alleviating chest pain associated with refractory angina.
​
The regenerative properties of umbilical cord MSCs—particularly their ability to promote tissue repair, stimulate new blood vessel formation, and enhance circulation—make them a promising option in the field of cardiovascular care. While more research is needed to fully evaluate long-term outcomes, the early results are highly encouraging and suggest that stem cell therapy could open a new chapter in the treatment of angina pectoris.
